Have all the ICD primary prevention trials excluded an important group of patients?
Primary prevention trials of implantable cardioverter defibrillator (ICD) therapy have generally excluded patients early after revascularization. Clinicians are commonly faced with patients who have ventricular dysfunction and nonsustained ventricular tachyarrhythmia developing shortly after revascularization. Since there are no evidence-based guidelines, management is currently at the discretion of the treating clinician. Recently, evidence has emerged that this patient population is at increased risk of development of life-threatening ventricular tachyarrhythmia and, pending prospective trials, we suggest that ICD therapy should be used in appropriately selected patients with perioperative ventricular arrhythmia.
Bolad
Islam
I
The Cardiac Arrhythmia Service, Lahey Medical Center, Burlington, Massachusetts 01805, USA.
Martin
David T
DT
D017147:Defibrillators, Implantable; D006801:Humans; D009204:Myocardial Revascularization; D018579:Patient Selection; D019990:Perioperative Care; D018754:Ventricular Dysfunction / Q000517:prevention & control*